MedTrace Logo

Efficacy and Safety of Xuesaitong Soft Capsule for Coronary Heart Disease Unstable Angina

NCT03083119 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2017-03-17

No results posted yet for this study

Summary

In this study, typical cases of coronary heart disease are selected. They will be intervened by Xuesaitong soft capsules to investigate efficacy and safety for Coronary Heart disease.

Conditions

Interventions

DRUG

Xuesaitong soft capsule

Panax Notoginseng Saponins, Specification:0.33 per bag, once take two pills and twice a day during a month.

DRUG

Placebo oral capsule

Xuesaitong soft capsule Placebo, soft capsule, once take two pills and twice a day during a month.

Sponsors & Collaborators

  • Jie Wang

    lead OTHER

Principal Investigators

  • Jie Wang · Guang Anmen Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-20
Primary Completion
2017-04-20
Completion
2017-08-20

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03083119 on ClinicalTrials.gov